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Background: Studies have shown that diminished serum arylesterase level is associated with states of high oxidative stress. It is used as a 
marker of diminishing antioxidant capabilities and as an independent factor in predicting adverse cardiac outcomes. Paraoxonase (PON), an HDL 
associated protein thought to mediate some of the atheroprotective functions of HDL, catalyzes endogenous serum arylesterase activity Nitric oxide 
(NO) is a potent endothelium-derived vasorelaxant produced from arginine via NO synthases, which can be inhibited by dysregulated methylated 
products of arginine such as symmetric dimethylarginine (SDMA). Decreased nitric oxide may lead to defective endothelial functionality and repair. 
We aimed to look at the relationship between arylesterase methylated arginine products and pulmonary pressures in patients with heart failure and 
pulmonary arterial hypertension, and Endothelial progenitor cell proliferation.
Methods:  We prospectively collected blood samples at the level of the pulmonary artery from 30 consecutive patients with advanced heart failure 
undergoing right heart catheterization. We measured serum arylesterase levels. Plasma metabolites of arginine metabolism and serum arylesterase 
levels were analyzed using mass and UV spectrophotometry respectively.
Results: In our study cohort (mean age 58±15 years, 63% male, 83% Caucasian,(median mPAP 33 mmHg interquartile range (IQR) [22-43] 
mmHg, and PCWP 14 IQR [19-25] mmHg). 66% had evidence of pulmonary hypertension . The median arylesterase levels were 92 IQR [72-112] uM. 
Patients with pulmonary hypertension ( mPAP > 25mmHG) had significantly lower arylesterase levels than those with lower mPAP, 86 IQR [70-98] vs. 
113 IQR [74-137] respectively, p=0.021. Also Patients with heart failure and a mPAP >25mm HG had higher levels of SDMA than those with lower 
pressures 18 IQR [6-10] vs 11 IQR [6-10] respectively. p=0.012
Conclusion: Patients with PH have lower HDL-associated PON-1 activity as measured by aryl, and is independent of dysregulated arginine 
metabolism.
